To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Adult patients with high-risk acute B-lymphoblastic leukemia
Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
Eligible for autologous hematopoietic stem cell transplantation
No major organ dysfunction
Combined with malignant tumors of other organs
With a serious infection that is not under control
Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
Patients who have had an allergic reaction to the drugs used in this study or similar drugs
Single group
Autologous hematopoietic stem cell transplantation combined with CD19-CART
Biological/VaccineAutologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
Relapse rate within 2 years
Non-relapse mortality
Progression-free survival
Overall survival rate
Incidence of infection
Click on the lead sponsor to view all of their trials.
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
Juventas Cell Therapy Ltd.
Collaborator
